Get the Stockscreener App
5.50
2.83%
-0.16
Olema Pharmaceuticals Inc stock is traded at $5.50, with a volume of 1.06M.
It is down -2.83% in the last 24 hours and down -9.84% over the past month.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
See More
Previous Close:
$5.66
Open:
$5.74
24h Volume:
1.06M
Relative Volume:
1.24
Market Cap:
$408.34M
Revenue:
-
Net Income/Loss:
$-96.66M
P/E Ratio:
-2.5581
EPS:
-2.15
Net Cash Flow:
$-83.73M
1W Performance:
+7.00%
1M Performance:
-9.84%
6M Performance:
-61.57%
1Y Performance:
-51.24%
1-Day Range:
$5.49
$5.93
1-Week Range:
$5.16
$5.93
52-Week Range:
$4.60
$16.77
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
(415) 651-3316
Address
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
5.50 | 408.34M | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-24 | Initiated | Goldman | Buy |
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
JPMorgan Chase & Co. Buys 157,171 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stock Holdings Increased by Hennion & Walsh Asset Management Inc. - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives $27.00 Consensus Target Price from Brokerages - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Form 424B5 Olema Pharmaceuticals, - StreetInsider.com
Barclays PLC Purchases 48,614 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Bain Capital Life Sciences Investors, LLC Acquires Significant Stake in Olema Pharmaceuticals Inc - GuruFocus.com
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Major Shareholder Acquires $1,728,000.00 in Stock - MarketBeat
Bain Capital Life Sciences buys $1.7m in Olema Pharmaceuticals stock - Investing.com Nigeria
Olema Pharmaceuticals announces equity security exchange By Investing.com - Investing.com Australia
Olema Pharmaceuticals announces equity security exchange - Investing.com India
Olema Pharmaceuticals stock hits 52-week low at $5.02 - Investing.com India
Olema Pharmaceuticals stock hits 52-week low at $5.02 By Investing.com - Investing.com South Africa
(OLMA) Investment Report - Stock Traders Daily
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Olema Pharmaceuticals Awards New Employee Stock Options for Cancer Drug Development Team - StockTitan
Olema Pharmaceuticals stock hits 52-week low at $5.55 By Investing.com - Investing.com Australia
Olema Pharmaceuticals stock hits 52-week low at $5.55 - Investing.com India
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Geode Capital Management LLC Decreases Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Geode Capital Management LLC Sells 125,170 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Barclays PLC Acquires 48,614 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Oncology Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateForm 8-K - Marketscreener.com
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion - MSN
State Street Corp Boosts Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Rating of “Buy” by Brokerages - Defense World
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Rating of "Buy" by Brokerages - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 7,616 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Top 3 Health Care Stocks That May Explode In Q4 - Benzinga
Olema Pharmaceuticals director Graham Walmsley sells $4.73m in stock By Investing.com - Investing.com Australia
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $4,730,136.75 in Stock - MarketBeat
Olema Pharmaceuticals director Graham Walmsley sells $4.73m in stock - Investing.com
(OLMA) Technical Pivots with Risk Controls - Stock Traders Daily
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Bought by Wellington Management Group LLP - MarketBeat
Charles Schwab Investment Management Inc. Increases Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Charles Schwab Investment Management Inc. Buys 207,565 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
What is HC Wainwright’s Forecast for OLMA FY2024 Earnings? - Defense World
What is HC Wainwright's Estimate for OLMA FY2024 Earnings? - MarketBeat
Olema Pharmaceuticals stock hits 52-week low at $7.67 By Investing.com - Investing.com Canada
Olema Pharmaceuticals stock hits 52-week low at $7.67 - Investing.com India
Olema Pharmaceuticals CEO Sean Bohen sells shares worth $986,365 By Investing.com - Investing.com Nigeria
Olema Pharmaceuticals, Inc. announced that it has received $249.999225 million in funding from a group of investors - Marketscreener.com
Olema Pharmaceuticals director sells shares worth $147,955 By Investing.com - Investing.com Nigeria
Olema Pharmaceuticals CEO Sean Bohen sells shares worth $986,365 - Investing.com
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):